Akero's Shares Soared 137% as Experimental NASH Drug Meets The Primary Endpoint In A Clinical Trial
Dow Jones2022-09-13
Shares of Akero Therapeutics Inc. soared 137.57% in premarket trading on Tuesday after the company said its experimental treatment for nonalcoholic steatohepatitis met a primary and secondary endpoint in a Phase 2b clinical trial.
NASH is a liver disease. "The magnitude and general consistency of results observed across the Phase 2a BALANCED and Phase 2b HARMONY studies increase the probability of success in Phase 3 and position EFX to potentially be a foundational monotherapy for patients with NASH," Dr. Stephen Harrison, one of the study's investigators, said in a news release.
Akero's stock is down 42.0% this year through Monday's close, while the broader S&P 500 has declined 13.7%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
